Free Trial

iHuman Inc. Sponsored ADR (NYSE:IH) Short Interest Update

iHuman logo with Consumer Discretionary background
Image from MarketBeat Media, LLC.

Key Points

  • Short interest surged 99.9% to 7,876 shares as of April 15, but still represents a negligible portion of the float with a days-to-cover ratio of roughly 0.5.
  • Institutional and analyst activity: Acadian Asset Management opened a new Q1 stake of 15,067 shares (~$32k), pushing institutional ownership to about 4.92%, while Weiss Ratings downgraded iHuman to a "sell" and the MarketBeat consensus is "Sell."
  • Dividend and valuation: The company announced a $0.10 annual dividend (ex-dividend April 17, payable May 15) implying an unusually high 573% yield at current prices; shares trade around $1.73 with a market cap of ~$88.4M, PE ~6.9, and last-quarter revenue of $27.25M (EPS $0.04).
  • Five stocks we like better than iHuman.

iHuman Inc. Sponsored ADR (NYSE:IH - Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totaling 7,876 shares, a growth of 99.9% from the March 31st total of 3,940 shares. Based on an average trading volume of 14,612 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.0% of the shares of the stock are sold short.

Institutional Trading of iHuman

An institutional investor recently bought a new position in iHuman stock. Acadian Asset Management LLC acquired a new stake in iHuman Inc. Sponsored ADR (NYSE:IH - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,067 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 4.92% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered iHuman from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, January 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Sell".

Get Our Latest Stock Report on IH

iHuman Stock Performance

Shares of NYSE IH traded down $0.03 during trading on Friday, hitting $1.73. 4,473 shares of the company were exchanged, compared to its average volume of 11,232. iHuman has a 12-month low of $1.55 and a 12-month high of $3.60. The company has a fifty day moving average price of $1.78 and a 200-day moving average price of $2.16. The firm has a market capitalization of $88.37 million, a PE ratio of 6.92 and a beta of 0.13.

iHuman (NYSE:IH - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.04 EPS for the quarter. iHuman had a return on equity of 9.79% and a net margin of 11.80%.The business had revenue of $27.25 million for the quarter.

iHuman Announces Dividend

The business also recently disclosed an annual dividend, which will be paid on Friday, May 15th. Investors of record on Friday, April 17th will be issued a $0.10 dividend. This represents a yield of 573.0%. The ex-dividend date is Friday, April 17th.

iHuman Company Profile

(Get Free Report)

iHuman Inc provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Writing, iHuman Fantastic Friends, and iHuman Readers; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo Town; and Aha World, an open-ended interactive app that nurtures a desire for discovery.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in iHuman Right Now?

Before you consider iHuman, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iHuman wasn't on the list.

While iHuman currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines